| Browse All

Century Therapeutics, Inc. (IPSC)

Healthcare | Biotechnology | Philadelphia, United States | NasdaqCM
2.60 USD +0.16 (6.557%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 2.62 +0.02 (0.738%) ⇧ (April 17, 2026, 6:43 p.m. EDT)

Short-term: ★★★★☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 11:42 p.m. EDT

Century Therapeutics is a high-conviction, risk-on biotech play supported by a robust balance sheet ($135M+ capital raise extends runway to 2029) and a catalyst-rich calendar for an FDA Part 2 stat for its lead T1D therapy. Despite negative revenue growth temporarily, the stock has decoupled from sector weakness, trading up while the broader sector stagnates. Options data confirms a speculative 'skew' positioning for upside rather than defensive hedging, validating the narrative that the stock's biggest risk is unrealized demand for its near-term progress milestones rather than immediate cash flow issues.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.153239
AutoETS0.154541
MSTL0.165052
AutoARIMA0.173121

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 75%
H-stat 1.15
Ljung-Box p 0.000
Jarque-Bera p 0.936
Excess Kurtosis -0.26
Attribute Value
Sector Healthcare
Debt to Equity Ratio 27.41
Revenue per Share 1.261
Market Cap 467,279,136
Forward P/E -4.91
Beta 1.67
Profit Margins -8.78%
Website https://www.centurytx.com

As of April 18, 2026, 11:42 p.m. EDT: Speculators are exhibiting a distinct bullish skew. In the July 2026 expiry, OTM call volume (28) significantly exceeds OTM put volume (0), while deep OTM calls at the 7.5 strike show massive Open Interest buildup (+188.5%). Volatility is highly skewed, with ATM call IV around 0.8-1.2 versus a notably higher ATM put IV of 2.76, indicating traders are pricing in downside risk rather than expecting it to be the primary driver. However, in the December 2027 horizon, the dynamic flips: massive ITM call volume (119 contracts) relative to OTM puts suggests long-term holders or unhedged bulls are accumulating. The current ATM anchor shows new call buying, reinforcing a short-to-intermediate-term upside bias.


Info Dump

Attribute Value
52 Week Change 3.814815
Address1 25 North 38th Street
Address2 11th Floor
All Time High 32.899
All Time Low 0.342
Ask 2.63
Ask Size 4
Average Daily Volume10 Day 1,411,120
Average Daily Volume3 Month 1,432,037
Average Volume 1,432,037
Average Volume10Days 1,411,120
Beta 1.67
Bid 2.57
Bid Size 8
Book Value 1.816
City Philadelphia
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 2.6
Current Ratio 5.971
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 2.63
Day Low 2.45
Debt To Equity 27.41
Display Name Century Therapeutics
Earnings Timestamp 1,773,318,600
Earnings Timestamp End 1,778,761,800
Earnings Timestamp Start 1,778,761,800
Ebitda -1,939,000
Ebitda Margins -0.017760001
Enterprise To Ebitda -203.058
Enterprise To Revenue 3.607
Enterprise Value 393,730,144
Eps Current Year -0.625
Eps Forward -0.53
Eps Trailing Twelve Months -0.14
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 2.2372
Fifty Day Average Change 0.36279988
Fifty Day Average Change Percent 0.16216694
Fifty Two Week Change Percent 381.4815
Fifty Two Week High 3.04
Fifty Two Week High Change -0.44000006
Fifty Two Week High Change Percent -0.14473686
Fifty Two Week Low 0.435
Fifty Two Week Low Change 2.165
Fifty Two Week Low Change Percent 4.977011
Fifty Two Week Range 0.435 - 3.04
Financial Currency USD
First Trade Date Milliseconds 1,624,023,000,000
Float Shares 97,533,739
Forward Eps -0.53
Forward P E -4.9056606
Free Cashflow -97,213,000
Full Exchange Name NasdaqCM
Full Time Employees 78
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.12364
Gross Profits 13,497,000
Has Pre Post Market Data 1
Held Percent Insiders 0.1283
Held Percent Institutions 0.58776003
Implied Shares Outstanding 179,722,750
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,021-06-18
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Long Name Century Therapeutics, Inc.
Market us_market
Market Cap 467,279,136
Market State CLOSED
Max Age 86,400
Message Board Id finmb_626518430
Most Recent Quarter 1,767,139,200
Net Income To Common -9,580,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 467,279,150
Number Of Analyst Opinions 2
Open 2.48
Operating Cashflow -103,876,000
Operating Margins -0.13777
Payout Ratio 0.0
Phone 267 817 5790
Post Market Change 0.019200087
Post Market Change Percent 0.7384649
Post Market Price 2.6192
Post Market Time 1,776,465,830
Previous Close 2.44
Price Eps Current Year -4.16
Price Hint 4
Price To Book 1.431718
Price To Sales Trailing12 Months 4.2805243
Profit Margins -0.08776
Quick Ratio 5.823
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.16
Regular Market Change Percent 6.55737
Regular Market Day High 2.63
Regular Market Day Low 2.45
Regular Market Day Range 2.45 - 2.63
Regular Market Open 2.48
Regular Market Previous Close 2.44
Regular Market Price 2.6
Regular Market Time 1,776,456,001
Regular Market Volume 1,877,261
Return On Assets -0.03259
Return On Equity -0.05982
Revenue Growth -1.0
Revenue Per Share 1.261
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 179,722,750
Shares Percent Shares Out 0.0573
Shares Short 10,289,543
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 6,332,990
Short Name Century Therapeutics, Inc.
Short Percent Of Float 0.0671
Short Ratio 6.27
Source Interval 15
State PA
Symbol IPSC
Target High Price 4.0
Target Low Price 2.0
Target Mean Price 3.0
Target Median Price 3.0
Total Cash 117,114,000
Total Cash Per Share 0.652
Total Debt 43,565,000
Total Revenue 109,164,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.14
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 1.145485
Two Hundred Day Average Change 1.4545149
Two Hundred Day Average Change Percent 1.2697808
Type Disp Equity
Volume 1,877,261
Website https://www.centurytx.com
Zip 19,104